Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Total Current Liabilities data on file, last reported at $17.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 281.56% year-over-year to $17.9 million in Q1 2026; TTM through Mar 2026 was $17.9 million, a 281.56% increase from a year earlier, with the FY2025 full-year figure at $18.1 million, up 263.12% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $17.9 million, down from $18.1 million in the prior quarter.
• Over the last five years, Total Current Liabilities for VVOS reached as high as $18.1 million in Q4 2025 and fell as low as $4.7 million in Q1 2025.
• Historically, Total Current Liabilities has averaged $8.0 million across 5 years, with a median of $6.8 million in 2022.
• Across the five-year window, Total Current Liabilities sank 41.75% in 2025 and jumped 281.56% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $6.8 million in 2022, then rose by 6.99% to $7.3 million in 2023, then plunged by 31.71% to $5.0 million in 2024, then surged by 263.12% to $18.1 million in 2025, then retreated by 0.77% to $17.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $17.9 million in Q1 2026, $18.1 million in Q4 2025, and $7.4 million in Q3 2025.